Majid joined Janux in June 2022 as executive director and head of clinical biomarkers responsible to devise strategy, source best technology and platforms and execute comprehensive laboratory testing plans in support of Janux clinical studies. Majid has over 15 years of experience in some of the most challenging areas of oncology therapeutics with a primary focus on predictive oncology clinical development. Trained as a translational pathologist he has held impactful positions with increasing responsibilities at large pharmaceutical and small to medium biotech companies including Novartis, Celgene, Juno Therapeutics, Five Prime, and Poseida Therapeutics.
Majid has a Doctor of Veterinary Medicine degree, a postgraduate diploma and a PhD from the University of Queensland in Australia.